南方医科大学学报 ›› 2013, Vol. 33 ›› Issue (11): 1632-.

• • 上一篇    下一篇

CD133和CD44在胃腺癌中的表达及其与E-cadherin的关系

陆国玉,吴晓飞,周蕾,俞岚,武世伍   

  • 出版日期:2013-11-20 发布日期:2013-11-20

Expressions of CD133 and CD44 in gastric adenocarcinoma and their relationship with E-cadherin expression

  • Online:2013-11-20 Published:2013-11-20

摘要: 目的探讨原发性胃腺癌(gastric adenocarcinoma, GAC)组织中CD133、CD44和E-cadherin蛋白表达的关系及临床病理
意义。方法应用免疫组织化学ElivisionTM plus法检测145例胃腺癌组织和30例正常胃黏膜组织中CD133、CD44和E-cadherin
蛋白的表达。结果在正常胃黏膜组织中,CD133、CD44和E-cadherin蛋白的阳性表达率分别为10.0%、3.3%和100%;在GAC
组中,CD133、CD44 和E-cadherin 蛋白的阳性表达率分别为46.9%、47.6%和42.8%,两组之间,差异均有显著性(P<0.05)。
CD133、CD44和E-cadherin蛋白的表达水平均与肿瘤的大小、分化程度、淋巴结转移与否、浸润深度、临床分期及术后生存期有
关(全部P<0.05);CD133的表达与CD44的表达呈正相关(P<0.05),CD133和CD44的表达均与E-cadherin的表达呈负相关(P<
0.005)。Kaplan-Meier 生存分析表明,CD133 和CD44 蛋白表达阳性的患者其生存率明显低于其阴性表达患者(P<0.001);
E-cadherin蛋白表达阳性的患者其生存率明显高于其阴性表达患者。Cox回归分析:CD133、CD44和E-cadherin的表达是影响
GAC患者术后生存率的独立预后因素。结论CD133、CD44和E-cadherin的表达水平在GAC组织中与肿瘤组织的大小、分化
程度、临床分期、浸润深度、淋巴结转移与否及预后等均有关;在GAC组织中联合检测CD133、CD44和E-cadherin对判断预后
有价值。

Abstract: Objective To explore the expression of CD133 and CD44 in the primary gastric adenocarcinoma (GAC) and their
relationship with the expression of E-cadherin. Methods The expressions of CD133, CD44, and E-cadherin was examined by
immunohistochemistry in 145 specimens of GAC tissues and 30 specimens of normal gastric tissues. Results The positivity
rates of CD133, CD44, and E-cadherin in normal gastric tissues were 10.0%, 0%, and 100%, respectively, showing significant
differences from the rates in GAC tissues (46.9%, 47.6%, and 42.8%, respectively) (P<0.05). The expressions of CD133, CD44,
and E-cadherin were significantly related with the tumor volume, differentiation, lymph node metastasis, invasive depth,
pathologic-tumor-node-metastasis (pTNM) stages, and postoperative-survival time (all P<0.05); a positive correlation was
found between the expression of CD133 and CD44, and they were both negatively correlated with E-cadherin expression (P<
0.005). Kaplan-Meier analysis showed a significant difference in the survival rate between CD133-positive and CD133-negative
patients (P<0.001) and between CD44-positive and CD44-negative patients; the patients with positive expression of E-cadherin
had a significantly longer survival than those negative for E-cadherin. Cox regression analysis indicated that CD133, CD44,
and E-cadherin expressions were all independent prognostic factors of GAC (all P<0.05). Conclusion The expressions of
CD133, CD44, and E-cadherin are related to the tumor volume, differentiation, pTNM stages, invasive depth, lymph node
metastasis, and prognosis of GAC, and their combined detection can be of important value in predicting the prognosis of GAC.